JP2017511305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511305A5 JP2017511305A5 JP2016556997A JP2016556997A JP2017511305A5 JP 2017511305 A5 JP2017511305 A5 JP 2017511305A5 JP 2016556997 A JP2016556997 A JP 2016556997A JP 2016556997 A JP2016556997 A JP 2016556997A JP 2017511305 A5 JP2017511305 A5 JP 2017511305A5
- Authority
- JP
- Japan
- Prior art keywords
- bond
- substituted
- unsubstituted
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 85
- 125000003118 aryl group Chemical group 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 77
- 125000001072 heteroaryl group Chemical group 0.000 claims description 72
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims description 51
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 48
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 48
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 43
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 43
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 125000000304 alkynyl group Chemical group 0.000 claims description 42
- 239000012190 activator Substances 0.000 claims description 35
- 125000002947 alkylene group Chemical group 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 125000004450 alkenylene group Chemical group 0.000 claims description 32
- 125000004419 alkynylene group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 229940124530 sulfonamide Drugs 0.000 claims description 13
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 6
- 125000005587 carbonate group Chemical group 0.000 claims description 6
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 6
- 125000004185 ester group Chemical group 0.000 claims description 6
- 125000001033 ether group Chemical group 0.000 claims description 6
- 150000007970 thio esters Chemical group 0.000 claims description 6
- -1 thioacid group Chemical group 0.000 claims description 6
- 125000000101 thioether group Chemical group 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- BEHLMOQXOSLGHN-UHFFFAOYSA-N benzenamine sulfate Chemical group OS(=O)(=O)NC1=CC=CC=C1 BEHLMOQXOSLGHN-UHFFFAOYSA-N 0.000 claims 7
- PXFORDPOPVGNJL-UHFFFAOYSA-N diphenylsulfamic acid Chemical class C=1C=CC=CC=1N(S(=O)(=O)O)C1=CC=CC=C1 PXFORDPOPVGNJL-UHFFFAOYSA-N 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 0 COC(N[C@@](C(N[C@@](Cc(cc1)ccc1NS(*)(=*)=O)c1c[s]c(-c2ccc[s]2)n1)=O)N=Cc1ccccc1)=* Chemical compound COC(N[C@@](C(N[C@@](Cc(cc1)ccc1NS(*)(=*)=O)c1c[s]c(-c2ccc[s]2)n1)=O)N=Cc1ccccc1)=* 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953680P | 2014-03-14 | 2014-03-14 | |
| US61/953,680 | 2014-03-14 | ||
| PCT/US2015/020425 WO2015138882A1 (en) | 2014-03-14 | 2015-03-13 | Hptp-beta inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018246712A Division JP6661744B2 (ja) | 2014-03-14 | 2018-12-28 | ＨＰＴＰ−β阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511305A JP2017511305A (ja) | 2017-04-20 |
| JP2017511305A5 true JP2017511305A5 (show.php) | 2018-04-12 |
| JP6483148B2 JP6483148B2 (ja) | 2019-03-13 |
Family
ID=54068203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556997A Active JP6483148B2 (ja) | 2014-03-14 | 2015-03-13 | ＨＰＴＰ−β阻害剤 |
| JP2018246712A Active JP6661744B2 (ja) | 2014-03-14 | 2018-12-28 | ＨＰＴＰ−β阻害剤 |
| JP2019077696A Withdrawn JP2019108407A (ja) | 2014-03-14 | 2019-04-16 | ＨＰＴＰ−β阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018246712A Active JP6661744B2 (ja) | 2014-03-14 | 2018-12-28 | ＨＰＴＰ−β阻害剤 |
| JP2019077696A Withdrawn JP2019108407A (ja) | 2014-03-14 | 2019-04-16 | ＨＰＴＰ−β阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9994560B2 (show.php) |
| EP (1) | EP3116503A4 (show.php) |
| JP (3) | JP6483148B2 (show.php) |
| CN (1) | CN106456614A (show.php) |
| WO (1) | WO2015138882A1 (show.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2648284C (en) | 2006-04-07 | 2016-08-16 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| ES2675891T3 (es) * | 2009-01-12 | 2018-07-13 | Akebia Therapeutics Inc. | Métodos para tratar el síndrome de fuga vascular |
| AU2010271105C1 (en) | 2009-01-12 | 2014-08-21 | Aerpio Therapeutics, Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| MX371382B (es) | 2013-03-15 | 2020-01-28 | Aerpio Therapeutics Inc | Composiciones, formulaciones y metodos para tratar enfermedades oculares. |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| EP3977994B1 (en) * | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| WO2019165349A1 (en) * | 2018-02-26 | 2019-08-29 | Aerpio Therapeutics, Inc. | METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPß INHIBITORS |
| WO2020012444A1 (en) * | 2018-07-13 | 2020-01-16 | Susan Quaggin | Ve-ptp inhibition in glaucoma |
| EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
| LT3873884T (lt) | 2018-10-30 | 2025-03-10 | Gilead Sciences, Inc. | 3-(chinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diono dariniai kaip alfa4beta7 integrino inhibitoriai, skirti uždegiminių ligų gydymui |
| PL3873900T3 (pl) | 2018-10-30 | 2025-06-02 | Gilead Sciences, Inc. | Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| WO2020214851A1 (en) * | 2019-04-18 | 2020-10-22 | Aerpio Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
| EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| GB2589400A (en) * | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| EP4013499A1 (en) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP4051267A4 (en) | 2019-10-29 | 2023-12-06 | EyePoint Pharmaceuticals, Inc. | TIE-2 SMALL MOLECULE ACTIVATORS |
| CN113060789A (zh) * | 2019-12-31 | 2021-07-02 | 大连乾丰生物科技有限公司 | 一种海蜇池塘水底质改良剂 |
| EP4262794A4 (en) * | 2020-12-18 | 2025-01-15 | EyePoint Pharmaceuticals, Inc. | METHOD FOR THE PRODUCTION OF LOW MOLECULAR WEIGHT ACTIVATORS OF TIE-2 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221584A (en) | 1979-02-09 | 1980-09-09 | Chevron Research Company | Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides |
| US4735961A (en) | 1984-05-07 | 1988-04-05 | Merck & Co., Inc. | Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety |
| PL186511B1 (pl) * | 1995-01-27 | 2004-01-30 | Novo Nordisk As | Nowe związki peptydowe, kompozycje farmaceutycznedo pobudzania uwalniania hormonu wzrostu i zastosowanie tych związków do wytwarzania leku do pobudzania uwalniania hormonu wzrostu |
| AU715621B2 (en) | 1995-04-06 | 2000-02-03 | Regeneron Pharmaceuticals, Inc. | TIE-2 ligands, methods of making and uses thereof |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| AU5154098A (en) | 1996-10-31 | 1998-05-22 | Duke University | Soluble tie2 receptor |
| US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
| US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| HK1043537A1 (zh) | 1999-03-26 | 2002-09-20 | Regeneron Pharmaceuticals, Inc. | 通過tie2受體激活劑調節血管通透性 |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| SK542003A3 (en) | 2000-06-23 | 2003-09-11 | Schering Ag | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use |
| AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| ES2290439T3 (es) * | 2002-02-25 | 2008-02-16 | Eli Lilly And Company | Moduladores del receptor activado del proliferador de peroxisomas. |
| WO2003084565A2 (en) | 2002-04-08 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| EP1572083A4 (en) | 2002-04-25 | 2008-09-24 | Univ Connecticut Health Ct | USE OF THERMAL SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC ADVANTAGE OF NON-VACCINAL TREATMENT MODALITY |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| CN1950342B (zh) | 2004-03-15 | 2012-09-26 | 詹森药业有限公司 | 作为阿片受体调节剂的新化合物 |
| TWI339659B (en) * | 2004-03-18 | 2011-04-01 | R Tech Ueno Ltd | Aqueous composition comprising thiazole derivative |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| DK1771474T3 (da) | 2004-07-20 | 2010-05-31 | Genentech Inc | Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf |
| EP1819355A4 (en) | 2004-09-28 | 2009-08-12 | Genexel Sein Inc | METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE |
| NZ556029A (en) | 2004-12-21 | 2010-04-30 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| CA2633211A1 (en) | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| CA2648284C (en) | 2006-04-07 | 2016-08-16 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| ES2612258T3 (es) | 2006-10-27 | 2017-05-16 | Sunnybrook Health Sciences Center | Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| EP2280601A4 (en) | 2008-02-21 | 2012-08-29 | Sequoia Pharmaceuticals Inc | AMINOACIDAL INHIBITORS OF CYTOCHROME P450 |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| ES2675891T3 (es) | 2009-01-12 | 2018-07-13 | Akebia Therapeutics Inc. | Métodos para tratar el síndrome de fuga vascular |
| AU2010271105C1 (en) | 2009-01-12 | 2014-08-21 | Aerpio Therapeutics, Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| WO2010101992A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| CA2753837A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| KR20140095105A (ko) | 2009-11-06 | 2014-07-31 | 에르피오 세러퓨틱스 인코포레이티드 | 대장염 치료용 조성물 및 방법 |
| US20110319455A1 (en) | 2010-04-19 | 2011-12-29 | Bruce Steven Klein | Antifungal Treatment |
| KR20130045341A (ko) | 2010-07-12 | 2013-05-03 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여 |
| PH12013500577B1 (en) * | 2010-10-07 | 2019-06-28 | Aerpio Therapeutics Inc | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| CN103249422A (zh) | 2010-12-02 | 2013-08-14 | 丸善制药株式会社 | Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物 |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| ES2774972T3 (es) | 2011-10-13 | 2020-07-23 | Aerpio Therapeutics Inc | Tratamiento de enfermedades oculares |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| CA2870341A1 (en) | 2012-04-13 | 2013-10-17 | The Johns Hopkins University | Treatment of ischemic retinopathies |
| DK3495387T3 (da) | 2012-07-13 | 2021-11-08 | Roche Glycart Ag | Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme |
| DK2880167T3 (en) | 2012-07-31 | 2018-07-30 | Univ Texas | METHODS AND COMPOSITIONS FOR IN VIVO-INDUCTION OF PANCREAS BETA CELL CREATION |
| MY177912A (en) | 2012-10-11 | 2020-09-25 | Ascendis Pharma Ophthalmology Div A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
| WO2014074823A1 (en) | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| WO2014079709A1 (en) | 2012-11-23 | 2014-05-30 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| MX371382B (es) | 2013-03-15 | 2020-01-28 | Aerpio Therapeutics Inc | Composiciones, formulaciones y metodos para tratar enfermedades oculares. |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| PT2983695T (pt) | 2013-04-11 | 2019-09-09 | Sunnybrook Res Inst | Métodos, usos e composições dos agonistas do tie2 |
| WO2014203182A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating choroidal neovascularisation |
| WO2014203183A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating macular edema |
| WO2015002893A1 (en) | 2013-07-02 | 2015-01-08 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| BR112016000282A2 (pt) | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
| MX2016000384A (es) | 2013-07-11 | 2016-04-29 | Novartis Ag | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. |
| EP2832746B1 (en) | 2013-07-29 | 2018-07-18 | Samsung Electronics Co., Ltd | Anti-Ang2 antibody |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| WO2015049243A1 (en) | 2013-10-01 | 2015-04-09 | Sphingotec Gmbh | A method for predicting the risk of getting a major adverse cardiac event |
| RS59000B1 (sr) | 2013-11-01 | 2019-08-30 | Regeneron Pharma | Intervencije zasnovane na angiopoietinu za lečenje cerebralne malarije |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| JP2015199733A (ja) | 2014-04-04 | 2015-11-12 | 国立大学法人東北大学 | 眼圧降下剤 |
| US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| US20160082129A1 (en) | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2015
- 2015-03-13 CN CN201580026210.0A patent/CN106456614A/zh active Pending
- 2015-03-13 US US14/657,276 patent/US9994560B2/en active Active
- 2015-03-13 EP EP15760687.2A patent/EP3116503A4/en not_active Withdrawn
- 2015-03-13 WO PCT/US2015/020425 patent/WO2015138882A1/en not_active Ceased
- 2015-03-13 JP JP2016556997A patent/JP6483148B2/ja active Active
-
2018
- 2018-05-07 US US15/972,863 patent/US10858354B2/en active Active
- 2018-12-28 JP JP2018246712A patent/JP6661744B2/ja active Active
-
2019
- 2019-04-16 JP JP2019077696A patent/JP2019108407A/ja not_active Withdrawn
-
2020
- 2020-10-02 US US17/062,098 patent/US20210130341A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511305A5 (show.php) | ||
| JP2012515776A5 (show.php) | ||
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| JP2008509166A5 (show.php) | ||
| CY1113873T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
| JP2017535555A5 (show.php) | ||
| AR067896A1 (es) | Procedimiento para sintetizar compuestos utiles para tratar hepatitis c | |
| JP2013032389A5 (show.php) | ||
| EP2360164A3 (de) | Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
| EP4328223A3 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR093047A1 (es) | Compuestos heterociclicos nitrogenados | |
| JP2015535839A5 (show.php) | ||
| HRP20191431T1 (hr) | Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida i njegovo pročišćavanje za uporabu kao aktivni farmaceutski pripravak | |
| JP2018530582A5 (show.php) | ||
| JP2017519796A5 (show.php) | ||
| ME01899B (me) | Disupstituisana jedinjenja tetrahidrofuranila kao antagonisti receptora bradikinina- b1 | |
| JP2006523626A5 (show.php) | ||
| RU2013140467A (ru) | Выделенные соединения из масла куркумы и способы применения | |
| ATE441627T1 (de) | Verfahren zur herstellung von valsartan | |
| EA201200726A1 (ru) | Способ синтеза, кристаллическая форма 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)ил]пропокси}бензамид гидрохлорида и фармацевтические композиции, которые ее содержат | |
| JP2018501266A5 (show.php) | ||
| RU2012136457A (ru) | Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad) | |
| JP2018536637A5 (show.php) | ||
| JP2020506879A5 (show.php) |